My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
February 2012
Top Stories
IDSA Urges Congress, FDA to Boost Antibiotic R&D

IDSA is working to address drug resistance and the dwindling antimicrobial research and development pipeline on multiple fronts. Recent activities include:

  • IDSA led a coalition of 50 organizations representing patients, providers, health systems, veterans, women and children’s health, seniors, and other stakeholders urging Congress to include economic incentives for antimicrobial development in legislation related to the Food and Drug Administration (FDA) (see letter (PDF)). The Society will continue to engage Congress as this legislation, one of the few “must-pass” bills this election year, moves forward.

  • As Congress considers federal funding for the 2013 fiscal year, IDSA will seek specific language in appropriations bills to help strengthen the nation’s response to antimicrobial resistance (and other ID priorities such as immunizations) by providing direction to federal agencies, in addition to calling for sufficient ID/HIV funding (see press release).

  • IDSA continues to urge FDA to quickly issue clear guidance to industry on anti-infective clinical trial designs. Collaborations with FDA have included workshops, advisory committee meetings, and an effort with the Foundation for the National Institutes of Health that brings together scientists from FDA, NIH, IDSA, industry, and academia (see press release). The goal: develop new regulatory standards for judging the efficacy of antibiotics in trials for therapies for skin infections and community-acquired bacterial pneumonia.

  • James Johnson, MD, FIDSA, a member of IDSA’s Antimicrobial Resistance Work Group, will represent IDSA at two upcoming congressional briefings focused on the use of antibiotics in animal agriculture. The briefings are titled “The Science Is Clear: Inappropriate Antibiotic Use in Animal Agriculture Threatens Public Health.”

To learn more, including details about IDSA’s 10 x ’20 initiative, which calls for the development of 10 new systemic antibiotics by 2020, and other antimicrobial resistance policy efforts, visit the Society’s website. To learn what you can do to help, see “From the President” in this issue.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:

Patient Care and Science
CDC Guidance for Influenza Antivirals Remains Unchanged
Medicare Website Reports Hospital CLABSI Rates
ACIP Recommends Tdap for All Adults, Including Those 65 and Older
Drug Approvals, Recalls, Adverse Events Update
Clinical Practice Management
Medicare Physician Payment Cuts Delayed for 10 Months
Global ID
Interview Series: CDC’s Role in Global HIV and TB
Experts Highlight Role of Prevention Interventions in Global AIDS Fight
PEPFAR Takes Hit in Obama’s FY2013 Budget
Policy and Advocacy
Obama’s FY2013 Budget Mixed Bag for ID, HIV/AIDS
HHS Advisory Group Recommends Voluntary Measures to Boost HCW Influenza Vaccination
Your Colleagues
Check Out “My IDSA” for Latest Member News
Education & Resources
CDC Lyme Disease Webinar: CME Credit Available
Adolescent Vaccination Education Materials Available
Top Stories
From the President:
How Is Antimicrobial Resistance Affecting Your Patients?
IDSA Urges Congress, FDA to Boost Antibiotic R&D
IDWeek 2012 Now Accepting Abstract Submissions
IDSA Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add '' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.